RxDoctor Payments Data

Hannah Whitesides

Nurse Practitioner · Charlotte, NCNPI 1376280198

Payments from drug & device makers

$2,086in general payments, 2019–2025

Across 76 payments — averaging $27.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$1K
  • Viiv Healthcare Company$350
  • Theratechnologies Inc.$111
  • Novo Nordisk$88
  • Lilly USA, LLC$74
  • Abbott$73
  • plus $351 from 10 others

What the payments were for

  • Food & beverage$2,086100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,086 in reported general payments places this provider in the 85th percentile of 4,393 nurse practitioner providers in North Carolina.

See all nurse practitioner providers in North Carolina

Medicare billing

Part B allowed, 2024
$14,172
Medicare patients
49
Services billed
185

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala260$1,000,859
TivicayDolutegravir Sodium66$161,683
DescovyEmtricitabine/Tenofov Alafenam68$143,001
DovatoDolutegravir Sodium/Lamivudine35$103,813
GenvoyaElviteg/Cob/Emtri/Tenof Alafen15$59,266
SymtuzaDarunavir/Cob/Emtri/Tenof Alaf13$56,668
JulucaDolutegravir/Rilpivirine16$53,826
OzempicSemaglutide42$49,438
JardianceEmpagliflozin51$41,605
MounjaroTirzepatide25$32,591
PifeltroDoravirine15$25,774
Darunavir19$25,177
RybelsusSemaglutide25$23,394
IsentressRaltegravir Potassium12$21,074
FarxigaDapagliflozin Propanediol11$7,315

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Descovy, Genvoya$1,039$1,203,126343 claims
Viiv Healthcare CompanyTivicay, Dovato, Juluca$350$319,322117 claims
Novo NordiskOzempic, Rybelsus$88$72,83267 claims
MerckPifeltro, Isentress$47$46,84827 claims
Boehringer IngelheimJardiance$63$41,60551 claims
Lilly USA, LLCMounjaro$74$32,59125 claims
AstraZenecaFarxiga$32$7,31511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,393 nurse practitioner providers in North Carolina.

Other nurse practitioner in Charlotte

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →